HEPACAM

Across TCGA pan-cancer cohorts, HEPACAM Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HEPACAM data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HEPACAM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HEPACAM expression acts as an unfavorable survival marker.

LIHC, PRAD, and ESCA are the cancer types where HEPACAM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.134	0.719	<.001	21	view →
PRAD	OS	Median	All	0.080	0.990	<.001	12	view →
ESCA	OS	Median	III,IV	0.102	0.574	<.001	12	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
BLCA	OS	Median	III,IV	0.239	0.683	.032	3	view →
SKCM	DFS	Median	All	0.256	0.644	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HEPACAM–LIHC (OS)

Open the LIHC breakdown →